PPP2R1B and esophageal cancer: On the other hand, PPP2R1B, an inhibitor of Akt phosphorylation, is inhibited by the upregulation of miR-200c, leading to cisplatin resistance in esophageal cancers through activation of the PI3K/Akt pathway [30].